Increased MAPK1/3 Phosphorylation in Luminal Breast Cancer Related with PIK3CA Hotspot Mutations and Prognosis

Overview

Journal Transl Oncol

Specialty Oncology

Date 2017 Sep 9

PMID 28886403

Citations 4

Authors

Diana Ramirez-Ardila

A Mieke Timmermans

Jean A Helmijr

John W M Martens

Els M J J Berns

Maurice P H M Jansen

Affiliations

Soon will be listed here.

Abstract

Introduction: While mutations in PIK3CA are most frequently (45%) detected in luminal breast cancer, downstream PI3K/AKT/mTOR pathway activation is predominantly observed in the basal subtype. The aim was to identify proteins activated in PIK3CA mutated luminal breast cancer and the clinical relevance of such a protein in breast cancer patients.

Materials And Methods: Expression levels of 171 signaling pathway (phospho-)proteins established by The Cancer Genome Atlas (TCGA) using reverse phase protein arrays (RPPA) were in silico examined in 361 breast cancers for their relation with PIK3CA status. MAPK1/3 phosphorylation was evaluated with immunohistochemistry on tissue microarrays (TMA) containing 721 primary breast cancer core biopsies to explore the relationship with metastasis-free survival.

Results: In silico analyses revealed increased phosphorylation of MAPK1/3, p38 and YAP, and decreased expression of p70S6K and 4E-BP1 in PIK3CA mutated compared to wild-type luminal breast cancer. Augmented MAPK1/3 phosphorylation was most significant, i.e. in luminal A for both PIK3CA exon 9 and 20 mutations and in luminal B for exon 9 mutations. In 290 adjuvant systemic therapy naïve lymph node negative (LNN) breast cancer patients with luminal cancer, high MAPK phosphorylation in nuclei (HR=0.49; 95% CI, 0.25-0.95; P=.036) and in tumor cells (HR=0.37; 95% CI, 0.18-0.79; P=.010) was related with favorable metastasis-free survival in multivariate analyses including traditional prognostic factors.

Conclusion: Enhanced MAPK1/3 phosphorylation in luminal breast cancer is related to PIK3CA exon-specific mutations and correlated with favorable prognosis especially when located in the nuclei of tumor cells.

Citing Articles

Network pharmacology-based approach to investigate the molecular targets of essential oil obtained from lavender for treating breast cancer.

Maitisha G, Zhou J, Zhao Y, Han S, Zhao Y, Abliz A Heliyon. 2023; 9(11):e21759.

PMID: 38034788 PMC: 10681924. DOI: 10.1016/j.heliyon.2023.e21759.

CircRNA casein kinase 1 gamma 1 (circ-CSNK1G1) plays carcinogenic effects in thyroid cancer by acting as miR-149-5p sponge and relieving the suppression of miR-149-5p on mitogen-activated protein kinase 1 (MAPK1).

Chen H, Li Q, Yi R, Li B, Xiong D, Peng H J Clin Lab Anal. 2022; 36(2):e24188.

PMID: 35023214 PMC: 8841138. DOI: 10.1002/jcla.24188.

Different properties of mammary carcinogenesis induced by two chemical carcinogens, DMBA and PhIP, in heterozygous BALB/c knockout mice.

Machida Y, Imai T Oncol Lett. 2021; 22(4):738.

PMID: 34466150 PMC: 8387855. DOI: 10.3892/ol.2021.12999.

Identification and Validation of PIK3CA as a Marker Associated with Prognosis and Immune Infiltration in Renal Clear Cell Carcinoma.

Li Y, Wang C, Gao Y, Zhou L J Oncol. 2021; 2021:3632576.

PMID: 34367282 PMC: 8337125. DOI: 10.1155/2021/3632576.

References

Beelen K, Opdam M, Severson T, Koornstra R, Vincent A, Wesseling J . Phosphorylated p-70S6K predicts tamoxifen resistance in postmenopausal breast cancer patients randomized between adjuvant tamoxifen versus no systemic treatment. Breast Cancer Res. 2014; 16(1):R6. PMC: 3979131. DOI: 10.1186/bcr3598. View

Wang G, Wong H, Konishi H, Blair B, Abukhdeir A, Gustin J . Single copies of mutant KRAS and mutant PIK3CA cooperate in immortalized human epithelial cells to induce tumor formation. Cancer Res. 2013; 73(11):3248-61. PMC: 3674106. DOI: 10.1158/0008-5472.CAN-12-1578. View

van der Willik K, Timmermans M, van Deurzen C, Look M, Reijm E, van Zundert W . SIAH2 protein expression in breast cancer is inversely related with ER status and outcome to tamoxifen therapy. Am J Cancer Res. 2016; 6(2):270-84. PMC: 4859659. View

Reijm E, Timmermans A, Look M, Meijer-van Gelder M, Stobbe C, van Deurzen C . High protein expression of EZH2 is related to unfavorable outcome to tamoxifen in metastatic breast cancer. Ann Oncol. 2014; 25(11):2185-2190. DOI: 10.1093/annonc/mdu391. View

Jerjees D, Alabdullah M, Alkaabi M, Abduljabbar R, Muftah A, Nolan C . ERK1/2 is related to oestrogen receptor and predicts outcome in hormone-treated breast cancer. Breast Cancer Res Treat. 2014; 147(1):25-37. DOI: 10.1007/s10549-014-3066-8. View

Ahmad D, Negm O, Alabdullah M, Mirza S, Hamed M, Band V . Clinicopathological and prognostic significance of mitogen-activated protein kinases (MAPK) in breast cancers. Breast Cancer Res Treat. 2016; 159(3):457-67. PMC: 5021722. DOI: 10.1007/s10549-016-3967-9. View

Beelen K, Opdam M, Severson T, Koornstra R, Vincent A, Wesseling J . PIK3CA mutations, phosphatase and tensin homolog, human epidermal growth factor receptor 2, and insulin-like growth factor 1 receptor and adjuvant tamoxifen resistance in postmenopausal breast cancer patients. Breast Cancer Res. 2014; 16(1):R13. PMC: 3978618. DOI: 10.1186/bcr3606. View

Deng G, Krishnakumar S, Powell A, Zhang H, Mindrinos M, Telli M . Single cell mutational analysis of PIK3CA in circulating tumor cells and metastases in breast cancer reveals heterogeneity, discordance, and mutation persistence in cultured disseminated tumor cells from bone marrow. BMC Cancer. 2014; 14:456. PMC: 4071027. DOI: 10.1186/1471-2407-14-456. View

Jensen J, Laenkholm A, Knoop A, Ewertz M, Bandaru R, Liu W . PIK3CA mutations may be discordant between primary and corresponding metastatic disease in breast cancer. Clin Cancer Res. 2010; 17(4):667-77. DOI: 10.1158/1078-0432.CCR-10-1133. View

10.

Ramirez-Ardila D, Helmijr J, Look M, Lurkin I, Ruigrok-Ritstier K, Van Laere S . Hotspot mutations in PIK3CA associate with first-line treatment outcome for aromatase inhibitors but not for tamoxifen. Breast Cancer Res Treat. 2013; 139(1):39-49. DOI: 10.1007/s10549-013-2529-7. View

11.

Loi S, Haibe-Kains B, Majjaj S, Lallemand F, Durbecq V, Larsimont D . PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer. Proc Natl Acad Sci U S A. 2010; 107(22):10208-13. PMC: 2890442. DOI: 10.1073/pnas.0907011107. View

12.

Beelen K, Hoefnagel L, Opdam M, Wesseling J, Sanders J, Vincent A . PI3K/AKT/mTOR pathway activation in primary and corresponding metastatic breast tumors after adjuvant endocrine therapy. Int J Cancer. 2014; 135(5):1257-63. PMC: 4277331. DOI: 10.1002/ijc.28769. View

13.

Cizkova M, Dujaric M, Lehmann-Che J, Scott V, Tembo O, Asselain B . Outcome impact of PIK3CA mutations in HER2-positive breast cancer patients treated with trastuzumab. Br J Cancer. 2013; 108(9):1807-9. PMC: 3658522. DOI: 10.1038/bjc.2013.164. View

14.

Hennessy B, Lu Y, Gonzalez-Angulo A, Carey M, Myhre S, Ju Z . A Technical Assessment of the Utility of Reverse Phase Protein Arrays for the Study of the Functional Proteome in Non-microdissected Human Breast Cancers. Clin Proteomics. 2011; 6(4):129-51. PMC: 3116520. DOI: 10.1007/s12014-010-9055-y. View

15.

Razis E, Bobos M, Kotoula V, Eleftheraki A, Kalofonos H, Pavlakis K . Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer. Breast Cancer Res Treat. 2011; 128(2):447-56. DOI: 10.1007/s10549-011-1572-5. View

16.

. Comprehensive molecular portraits of human breast tumours. Nature. 2012; 490(7418):61-70. PMC: 3465532. DOI: 10.1038/nature11412. View

17.

Zehorai E, Yao Z, Plotnikov A, Seger R . The subcellular localization of MEK and ERK--a novel nuclear translocation signal (NTS) paves a way to the nucleus. Mol Cell Endocrinol. 2009; 314(2):213-20. DOI: 10.1016/j.mce.2009.04.008. View

18.

Esteva F, Guo H, Zhang S, Santa-Maria C, Stone S, Lanchbury J . PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer. Am J Pathol. 2010; 177(4):1647-56. PMC: 2947262. DOI: 10.2353/ajpath.2010.090885. View